Welcome to our dedicated page for Ani Pharmaceutic SEC filings (Ticker: ANIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ANI Pharmaceuticals, Inc. filings document financial results, operating updates, governance matters, and material events for its Rare Disease, Generics, and Brands businesses. Form 8-K reports furnish earnings releases, preliminary results, guidance updates, Regulation FD investor presentations, and corporate changes such as independent auditor matters.
ANI proxy filings cover shareholder voting items, board governance, executive compensation, equity awards, and related governance disclosures. The filing record also provides formal context for product and business risks tied to biopharmaceutical development, FDA-regulated generic launches, branded products, commercialization, manufacturing, and capital actions.
ANI Pharmaceuticals executive Christopher Mutz reported recent stock transactions in ANI PHARMACEUTICALS INC common shares. He sold 2,121 shares on March 6, 2026 at $74.22 per share and 3,602 shares on March 9, 2026 at $74.18 per share, both as open‑market sales under a Rule 10b5‑1 trading plan adopted on June 16, 2025. Separately, 3,314 shares were withheld on March 7, 2026 at $74.04 per share to cover tax obligations tied to the vesting of 6,476 restricted shares. After these transactions, he directly holds 94,471 shares of ANI common stock.
ANI Pharmaceuticals President & CEO Nikhil Lalwani reported a tax-related share disposition. On the reported date, 17,060 shares of common stock were withheld at a price of $74.04 per share to cover tax obligations tied to the vesting of 33,352 previously granted restricted shares.
These withheld shares were not an open-market sale but a payment of tax liability. After this withholding, Lalwani directly owned 404,889 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals SVP, Generics Ori Gutwerg had 3,314 shares of Common Stock withheld on March 7, 2026 to cover tax obligations at $74.04 per share. The shares were tied to the vesting of 6,476 restricted shares, and Gutwerg now holds 81,468 shares directly.
ANI Pharmaceuticals senior executive Krista Davis reported open-market sales of company stock. As SVP and Chief HR Officer, she sold 6,572 shares of ANI Pharmaceuticals common stock in two transactions at prices of $74.13 and $75.00 per share. These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 18, 2025, indicating they were scheduled in advance rather than timed discretionarily. Following the transactions, Davis directly holds 51,946 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals SVP & CFO Stephen P. Carey reported a tax-related share disposition. On the vesting of 11,292 shares of restricted stock that had been granted earlier, 5,150 shares of common stock were withheld at $74.04 per share to cover tax obligations, a non-market transaction exempt under Rule 16(b)-3. After this withholding, Carey directly holds 180,393 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals senior vice president and CFO Stephen P. Carey reported both an option exercise and share sales. He exercised options for 3,312 shares at $49.51 per share, then sold a total of 7,312 common shares in open‑market trades at prices around $75.42–$75.56. Following these transactions, he directly holds 185,543 shares of common stock and 9,938 stock options.
Morgan Stanley Smith Barney LLC Executive Financial Services submitted a Form 144 notice proposing resale of common stock. The filing lists 4,000 restricted shares dated 04/10/2024 and 3,312 shares tied to a stock option exercise dated 03/05/2026.
ANI Pharmaceuticals reported that Christopher Mutz, its Head of Rare Disease, sold 417 shares of common stock in an open-market transaction at $74 per share. After this sale, he directly owns 103,508 shares. The sale was made under a pre-established Rule 10b5-1 trading plan adopted by the reporting person.
ANI Pharmaceuticals senior vice president Ori Gutwerg reported an open-market sale of company stock. On March 3, 2026, he sold 2,060 shares of Common Stock at a price of $76.50 per share. After this transaction, he directly owned 84,782 common shares.
ANI Pharmaceuticals director Patrick D. Walsh reported an open-market sale of 6,000 shares of common stock at $74.23 per share on March 3, 2026. After this transaction, he directly holds 52,405 shares.